JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.4
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 15, Issue 4 (2023)
Iran J War Public Health 2023, 15(4): 435-439 |
Back to browse issues page
Article Type:
Subject:
Ethics code: IR.IUMS.FMD.REC.1399.827
History
Received: 2023/11/29 | Accepted: 2024/04/4 | Published: 2024/04/20
Received: 2023/11/29 | Accepted: 2024/04/4 | Published: 2024/04/20
How to cite this article
Tavassoli F, Aghabiklooei A, Azimi M, Baghai Wadji M, Ahmadi S, Ameri M. Economics of Hospitalization and Medication Therapy for Old COVID-19 Patients; an Experience from a Tertiary Center in Iran. Iran J War Public Health 2023; 15 (4) :435-439
URL: http://ijwph.ir/article-1-1417-en.html
URL: http://ijwph.ir/article-1-1417-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
1- Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
2- “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Forensic Medicine, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran
3- “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Internal Medicine, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran
4- “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Surgery, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran
5- “Preventive Medicine and Public Health Research Center” and “Psychosocial Health Research Institute”, Iran University of Medical Sciences, Tehran, Iran
2- “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Forensic Medicine, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran
3- “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Internal Medicine, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran
4- “Firoozgar Clinical Research Development Center (FCRDC)” and “Department of Surgery, Faculty of Medicine”, Iran University of Medical Sciences, Tehran, Iran
5- “Preventive Medicine and Public Health Research Center” and “Psychosocial Health Research Institute”, Iran University of Medical Sciences, Tehran, Iran
Abstract (635 Views)
Aims: There are controversies about the expenditures imposed on surveillance in the treatment of elderly patients and patients with end-stage disease. The present health economic evaluation study was performed to find the cost-effectiveness of hospitalization and antiviral treatment of COVID-19 in elderly patients.
Instrument & Methods: A health economic evaluation as a single-center primary study with a cross-sectional design was performed in Firoozgar Hospital, Tehran, Iran, in 2022. All the hospitalized cases of COVID-19 at 65 years of age and more were eligible for the study. The health outcomes were the length of stay and death. Cost-effectiveness was calculated using the incremental cost-effectiveness ratio. Stata14 was used for data analysis.
Findings: Of the admitted patients, 347 cases over 65 were selected for the study. 173 patients (49.86%) were in the age range of 65-74, 69 patients (31.41%) were in the age range of 75-84, and 65 patients (18.73%) were 85 and more. One hundred ninety-nine patients (57.35%) survived, and 148 patients (42.65%) died. The mean of LoS was 11.40±7.01 days, with the mean at the ward being 5.24±5.44 days and at the ICU 6.15±6.94 days. The mean cost of a bed day was 35.41±32.03 dollars, with a right-skewed distribution.
Conclusion: A mean cost of 88.711$ is needed for the survival of one patient, assuming that all the ICU-needed patients would die if there was a lack of hospital admission. Considering all ward and ICU admitted patients, 44.854$ is needed to save one old patient's life, assuming this logic.
Instrument & Methods: A health economic evaluation as a single-center primary study with a cross-sectional design was performed in Firoozgar Hospital, Tehran, Iran, in 2022. All the hospitalized cases of COVID-19 at 65 years of age and more were eligible for the study. The health outcomes were the length of stay and death. Cost-effectiveness was calculated using the incremental cost-effectiveness ratio. Stata14 was used for data analysis.
Findings: Of the admitted patients, 347 cases over 65 were selected for the study. 173 patients (49.86%) were in the age range of 65-74, 69 patients (31.41%) were in the age range of 75-84, and 65 patients (18.73%) were 85 and more. One hundred ninety-nine patients (57.35%) survived, and 148 patients (42.65%) died. The mean of LoS was 11.40±7.01 days, with the mean at the ward being 5.24±5.44 days and at the ICU 6.15±6.94 days. The mean cost of a bed day was 35.41±32.03 dollars, with a right-skewed distribution.
Conclusion: A mean cost of 88.711$ is needed for the survival of one patient, assuming that all the ICU-needed patients would die if there was a lack of hospital admission. Considering all ward and ICU admitted patients, 44.854$ is needed to save one old patient's life, assuming this logic.
Keywords:
References
1. Smith Jervelund S, Eikemo TA. The double burden of COVID-19. Scand J Public Health. 2021;49(1):1-4. [Link] [DOI:10.1177/1403494820984702]
2. Khan JR, Awan N, Islam MM, Muurlink O. Healthcare capacity, health expenditure, and civil society as predictors of COVID-19 case fatalities: a global analysis. Front Public Health. 2020;8:347. [Link] [DOI:10.3389/fpubh.2020.00347]
3. Di Fusco M, Shea KM, Lin J, Nguyen JL, Angulo FJ, Benigno M, et al. Health outcomes and economic burden of hospitalized COVID-19 patients in the United States. J Med Econ. 2021;24(1):308-17. [Link] [DOI:10.1080/13696998.2021.1886109]
4. Bisht R, Saharia R, Sarma J. COVID-19 and the burden of ill-health: a double crisis of disruptions and inequalities. J Soc Econ Dev. 2021;23:342-56. [Link] [DOI:10.1007/s40847-020-00117-x]
5. Levin AT, Owusu-Boaitey N, Pugh S, Fosdick BK, Zwi AB, Malani A, et al. Assessing the burden of COVID-19 in developing countries: systematic review, meta-analysis and public policy implications. BMJ Glob Health. 2022;7(5):e008477. [Link] [DOI:10.1136/bmjgh-2022-008477]
6. Chan AHY, Horne R. Preventing a post-pandemic double burden of disease in the COVID-19 pandemic. Glob Adv Health Med. 2021;10:21649561211010137. [Link] [DOI:10.1177/21649561211010137]
7. Haldane V, De Foo C, Abdalla SM, Jung A-S, Tan M, Wu S, et al. Health systems resilience in managing the COVID-19 pandemic: lessons from 28 countries. Nat Med. 2021;27(6):964-80. [Link] [DOI:10.1038/s41591-021-01381-y]
8. Reddy SG. Population health, economics and ethics in the age of COVID-19. BMJ Glob Health. 2020;5(7):e003259. [Link] [DOI:10.1136/bmjgh-2020-003259]
9. Figari F, Fiorio C. Welfare resilience in the immediate aftermath of the COVID-19 outbreak in Italy. Covid Economics. 2020;2020(8):106-33. [Link] [DOI:10.4324/9781003095590-7]
10. Herron TL, Manuel T. Ethics of US government policy responses to the COVID‐19 pandemic: A utilitarianism perspective. Business Soc Rev. 2022;127(51):343-67. [Link] [DOI:10.1111/basr.12259]
11. Hodges R, Caperchione E, Van Helden J, Reichard C, Sorrentino D. The role of scientific expertise in COVID-19 policy-making: evidence from four European countries. Public Organization Rev. 2022;22(2):249-67. [Link] [DOI:10.1007/s11115-022-00614-z]
12. Mazza M, Attanasio M, Pino MC, Masedu F, Tiberti S, Sarlo M, Valenti M. Moral decision-making, stress, and social cognition in frontline workers vs. population groups during the COVID-19 pandemic: An explorative study. Frontiers in psychology. 2020;11:588159. [Link] [DOI:10.3389/fpsyg.2020.588159]
13. Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A cost-effectiveness framework for COVID-19 treatments for hospitalized patients in the United States. Adv Ther. 2021;38(4):1811-31. [Link] [DOI:10.1007/s12325-021-01654-5]
14. Li B, Chen L, Shi L. Determinants of Hospitalization Costs among Moderate Cases of COVID-19. INQUIRY. 2022;59:00469580211059483. [Link] [DOI:10.1177/00469580211059483]
15. Richards F, Kodjamanova P, Chen X, Li N, Atanasov P, Bennetts L, et al. Economic burden of COVID-19: A systematic review. Clinicoecon Outcomes Res. 2022:293-307. [Link] [DOI:10.2147/CEOR.S338225]
16. Kolbin A, Belousov DY, Gomon YM, Balykina YE, Ivanov I. Socio-economic burden of COVID-19 in the Russian Federation. Value Health. 2020;23:S556. [Link] [DOI:10.1016/j.jval.2020.08.906]
17. Coast J, Flynn T, Sutton E, Al-Janabi H, Vosper J, Lavender S, et al. Investigating Choice Experiments for Preferences of Older People (ICEPOP): Evaluative spaces in health economics. J Health Services Res Policy. 2008;13(3 suppl):31-7. [Link] [DOI:10.1258/jhsrp.2008.008024]
18. Li Y, Mutchler JE. Older adults and the economic impact of the COVID-19 pandemic. J Aging Soc Policy. 2020;32(4-5):477-87. [Link] [DOI:10.1080/08959420.2020.1773191]
19. Kar N. COVID-19 and older adults: In the face of a global disaster. J Geriatric Care and Res. 2020;7(1):1-2. [Link]
20. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: A report of the ISPOR CHEERS II Good Practices Task Force. Value in Health. 2022;25(1):10-31. [Link] [DOI:10.1016/j.jval.2021.10.008]
21. Weiss M, Grom F, Porzsolt F. Costs of additional treatment success (COATS) based on numbers needed to treat (NNT) is a simplified calculation method to facilitate physicians medical decisions with regards to monetary costs. Br J Med Medical Res. 2012;2(4):636. [Link] [DOI:10.9734/BJMMR/2012/1379]
22. Boonacker CW, van der Veen EL, van der Wilt GJ, Schilder AG, Rovers MM. Trimethoprim-sulfamethoxazole in children with chronic otitis media: A randomized comparison of costs and effects. Otol Neurotol. 2008;29(7):961-4. [Link] [DOI:10.1097/MAO.0b013e3181859a66]
23. Daddoust L, Khankeh H, Ebadi A, Sahaf R, Nakhaei M, Asgary A. The vulnerability of the Iranian elderly in disasters: Qualitative content analysis. Iran J Nurs Midwifery Res. 2018;23(5):402-8. [Link] [DOI:10.4103/ijnmr.IJNMR_127_17]
24. Ghaffari Darab M, Keshavarz K, Sadeghi E, Shahmohamadi J, Kavosi Z. The economic burden of coronavirus disease 2019 (COVID-19): Evidence from Iran. BMC Health Serv Res. 2021;21(1):1-7. [Link] [DOI:10.1186/s12913-021-06126-8]
25. Rezapour A, Souresrafil A, Peighambari MM, Heidarali M, Tashakori-Miyanroudi M. Economic evaluation of programs against COVID-19: A systematic review. Int J Surg. 2021;85:10-8. [Link] [DOI:10.1016/j.ijsu.2020.11.015]
26. Panneer S, Kantamaneni K, Palaniswamy U, Bhat L, Pushparaj RRB, Nayar KR, et al. Health, Economic and Social Development Challenges of the COVID-19 Pandemic: Strategies for Multiple and Interconnected Issues. Healthcare (Basel). 2022;10(5):770. [Link] [DOI:10.3390/healthcare10050770]
27. Baidhowi AD. Human Rights for The Elderly Group in Indonesia: Elderly in The Era of Covid 19. NEGREI. 2022;2(1):23-34. [Link] [DOI:10.29240/negrei.v2i1.3629]